Abstract

Si}&^ c@^!^ i• & `!!^}c|^ }[æ]]![c^å çæ&&i}^ [• {æ|| { [|^&`|^ c@^!æ]^`ci& [} e@^ {æ!\^c, c@^ !^&^}c *![àæ] [`cà!^æ\ [- SARS-C[V-2, _@i&@ @æ }^æ!]^ 15 { i||i[] i }·^&c^å]^[]|^ æ}å { [!^ c@æ} 600,000 -æcæ]ici^• (æ&&^••^å [} 20c@ J`|^ 2020),][•^• æ •i*}i, &æ}c &@æ||^} *^ c[æ]| }æci[]• æ}å •[&i^ci. N^æ!|^ 1500 i}c^•ci*æci[] *#!^ æ&c^*c[] ^}![||i}*] æci^}c•à^ i}ciæci[] -[! &|i}i&æ] !^•^æ!&@ æ*æi}•c COVID-19 à^&æ`•^ c[] c@^ `!*^}c }^^å -[! æ &æ`•æcic^ therapy.

 $T @^{ \{ai\}} [c^{ae^{-} [-C[!] ac_{ii}^{i} \cdot \cdot \cdot , \& @^{ \{ [c'_1] \cdot i\} - [i'_1] ! [c^{ae^{-} (3CL] ! [])},] ! [\&^{-e^{-} e^{0} | @!^{*} -] [|^{-}] ! [c^{i}] 1 a b i 1 a b$

 $\begin{aligned} & = \left[\left\{ -\frac{1}{2} \left\{ -\frac{1}{2} \right\} \right\} & = \left\{ -\frac{1}{2} \left\{ -\frac{1}{2} \right\} \\ & = \left\{ -\frac{1}{2} \left\{ -\frac{1}{2} \right\} \\ & = \left\{$

Citation: Fishwick CWG (2022) Utilizing Virtual Screening and Structure-Based Drug Design to Repurpose Approved Medications as Possible Inhibitors of the 3CL-Protease of the SARS-Cov-2. J Cell Mol Pharmacol 6: 135.

Page 2 of 3

D, c, . .

2019 _ Т) • A) · · ://. A B**-** 14: , В ۲ X В (1 В--:6 7) 145 145 I А X 4.5 3 Т A A 2004)

14:A 50 В _/ B 10 A В 14:X 3 A

 Citation: Fishwick CWG (2022) Utilizing Virtual Screening and Structure-Based Drug Design to Repurpose Approved Medications as Possible Inhibitors of the 3CL-Protease of the SARS-Cov-2. J Cell Mol Pharmacol 6: 135.

Page 3 of 3

В ØA. . -Α. NA ۰. . 1 ØA. . . . 3 l 1 B) . . . **,**). I ,1 ۱ 50 В A Т 1. Т '। А ., . B Т B ۱ B / 1. • 3 / . 145. • Т 1 2. - -٠ . . •

- -• I 1 1 ۱ А . I I . B 3 I Т 3 A ø 1 1 T . ï I . Т T 1 1

C c



References

- Bæ^|| JB, H[||[,æ^ GA (2010) N^, •`à•cl*&c'i^, |c^i• -[| !^{ [çæ| [-] æ} æ•eæ^ åjc^i-^!^}&^ &[[] [`}å• (PAINS) -[[{ •&!^^}i]* |jàlælå^• æ}å -[| c@^å] ^¢&|`•i[] i} ài[æ•eæ^•.J M^å C@^ { 2719-2740.
- Bæb[iæc@ J, P^lcæ•[} L, Wæ ^l M (2009) Næçi*æci}* •cl*&c*l^-æ&ciçic° landscapes. Dl** Di•&[c T[åæ^ 14 (13.14): 698-705.
- B^\\\^ M, Fi^\åi} * BC, Gæ {i^\åi^} J (2015) P[c^\cia#) à\[æâ S]^&c\` { i}@iàic[i• [-c@^ &[\] æçi\`• 3CL]\[æçi\cia#) •&\^^}i} * æ)å •c\`&c`\^-àæ•^å å\`* å^•i*}.
 •c`å^Vi\`•^•7 (12): 6642-6660.
- Cæ]^{*}::åSJ, M^{*}¦æ:[çEN, T¦[]•®æP@æ}c[{A (2017) Problems with the Utility of A|^\c• -[¦Pæ}-A••æ[^] INc^¦-^\^}&^C[{][^{*}}å. J C®^{ I}- M[å^| 57 (3): 417-427.
- C[:c^*iæ}i A, I}*[*|iæ G, I]][ic[M, Giæ!!ææ}[A (2020) A ••c^ {æci& !^çi^, [} c@^ ^ &æ& a)å •æ-^c^ [- &@|[![~~i}^--[! c@^ c!^æc { ^}c [- COVID-19. J Crit Cæ!^ 57 (3): 417-427.
- D[}* E, D^{*} EL, Gælå}^! L (2020) A} i}c^\æ&cc^, ^à-àæ•^å åæ•@à[ælå c[clæ&\ COVID-19 i} ¦^æ| ci {^ Læ}&c. I}-^&c Di• 7 (12): 6642-6660.
- Fæ} HH, Wæ}* LQ (2020) R^]^{*}|] [•i}* [-&[i]ii&æ]|*æ]]![ç^â å!^{**}•-[!c!^æc {^c [-&[![]æçii^{*}• åi•^æ•^ 2019 i] æ 2019-][ç^l &[![]æçii^{**}•. Model Chin Med J.
- Bæ[J, Tiæ} Z, Ÿæ} Ý (2020) B¦^æ\c@![`*@ C@![![``i}^]@[•]@æc^@æ••@[,}
 æ]]æ!^}c^ &æ&^ij c!^æc{^}c [- COVID-19 æ••[&iæc^å]}^`{[]iæ i} &|i}i&æ]
 eč'åi^•. Bi[•&i T¦^}å• 14 (1): 72-73.
- 9. F|^¢}^¦ C (1998) HIV-]¦[c^æ•^ å}@ààc[¦• N E}*| J M^å 338: 1281-1292.
- 10. G@[•@ AK, O•• , ælå HL (2016) P!æc[R^&^}c]+[*¦^•• i} c@^ å^ç^[] {^}c [-HIV-1]+[c^æ•^ i}@iàic[i• -[¦ c@^ c!^æc {^}c [- HIV/AIDS. J M^å C@^ { 59 (11): 5172-5208.
- Lç Z, Cũ[°] Ÿ,Wæ}* Ÿ(2015) HIV]¦[ũ^œ•^ i}@iàic[i• æ i^çi^, [- { [|^&`|æ| selectivity and toxicity. HIV AIDS R^• Pæ|liæ: Cæ\⁺ 7:95-104.
- Bæ^|| JB, H[||[, æ^ G (2010) N^, •`à•cl^{*}&c^{*}, |c^1• -[! !^{ [cæ| [-] æ} æ•æ^ i}c^1-^!^}&^ &[[] [`}å• (PAINS) -![{ •&!^^}i} iàiæii^• æ}ā -[! c@^i; ^¢&|`•i[} i} àiæ•ex^{*}. J M^ā C@^ { 2719-2740.
- 14. Pæc^¦•[} DL, S i}å^||• S, M[@¦ J, B¦^•c^¦ M (2000) Aå@^!^}&^ c[]¦[c^æ•^ i}@iààc[¦ c@^!æ]^ æ}å [čc&[{^•i}]æci^}c• , ic@ HIV i}-^&ci[}. A}] I}c^¦} M^å 133 (1): 21-30.
- 15. P¦&^ GW, G[č|å PS, Mæł• A (2014)U•^ [--;!^^| æçæijæà|^ æ}å []^} •[č|&^ tools for in silico screening in chemical biology. J C@^ { Eåč& 91 (4): 602-604.